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PhOBJECTIVES This study sought to describe the angiographic characteristics, strategy associated with perforation, and
the management of perforation during chronic total occlusion percutaneous coronary intervention (CTO PCI).
BACKGROUND The incidence of perforation is higher during CTO PCI compared with non-CTO PCI and is reportedly
highest among retrograde procedures.
METHODS Among 1,000 consecutive patients who underwent CTO PCI in a 12-center registry, 89 (8.9%) had core
lab–adjudicated angiographic perforations. Clinical perforation was defined as any perforation requiring treatment. Major
adverse cardiac events (MAEs) were defined as in-hospital death, cardiac tamponade, and pericardial effusion.
RESULTS Among the 89 perforations, 43 (48.3%) were clinically significant, and 46 (51.7%) were simply observed.
MAE occurred in 25 (28.0%), and in-hospital death occurred in 9 (10.1%). Compared with nonclinical perforations,
clinical perforations were larger in size, more often at a collateral location, had a high-risk shape, and less likely to cause
staining or fast filling. Compared with perforations not associated with MAE, perforations associated with MAE were
larger in size, more proximal or at collateral location, and had a high-risk shape. When the core lab attributed the
perforation to the approach used when the perforation occurred, 61% of retrograde perforations by other classifications
were actually antegrade.
CONCLUSIONS Larger size, proximal or collateral location, and high-risk shapes of a coronary perforation were
associated with MAE. Six of 10 perforations occurred with antegrade approaches among patients who had both
strategies attempted. These finding will help emerging CTO operators understand high-risk features of the
perforation that require treatment and inform future comparisons of retrograde and antegrade complications.
(J Am Coll Cardiol Intv 2019;12:1902–12) © 2019 by the American College of Cardiology Foundation.N 1936-8798/$36.00 https://doi.org/10.1016/j.jcin.2019.05.024
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FIGURE 1 Flow Diagram of Analytic Population
AB BR E V I A T I O N S
AND ACRONYM S
ADR = antegrade dissection
re-entry
AWE = antegrade wire
escalation
CABG = coronary artery bypass
grafting
CTO = chronic total occlusion
MAE = major adverse events
PCI = percutaneous coronary
vention
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1903C oronary perforations in percutaneous coro-nary intervention (PCI) occur rarely (0.50%to 0.58%) (1,2), but are higher during chronic
total occlusion (CTO) PCI (1.4% to 4.4%) (3,4) and is
reportedly highest among retrograde procedures (5).
These prior studies attributed perforation and other
complications to the retrograde approach if any
attempt at collateral access was made, yet some
hybrid CTO procedures may have involved both
strategies—full antegrade attempt with perforation
followed by retrograde bailout—making attribution
of complications inaccurate by this method. More-
over, the characteristics of perforation during CTO
PCI and those that require treatment have not been
previously described.
To address these knowledge gaps, we analyzed a
consecutive cohort of 1,000 patients from 12 U.S.
centers undergoing CTO PCI of whom 89 angiographic
perforations were observed in the OPEN-CTO (Out-
comes, Patient health status, and Efficiency iN
Chronic Total Occlusion hybrid procedures) study.
We examined the patient characteristics, procedural
technique treatment strategy, adverse outcomes, and
detailed characteristics of the perforations in patients
undergoing CTO PCI.OPEN-CTO ¼ Outcomes, Patient health status, and Efficiency iN Chronic Total Occlusion
hybrid procedures registry.
SEE PAGE 1913METHODS
STUDY POPULATION. The OPEN-CTO study is a pro-
spective, single-arm registry that enrolled consecu-
tive patients with CTOs who underwent attempted
CTO PCI at 12 U.S. sites. Although the complete study
methods have been published previously (6), in brief,
eligible patients were >18 years of age and had
symptoms suggestive of ischemic heart disease, with
Thrombolysis In Myocardial Infarction (TIMI) flow
grade 0 and a lesion that was thought to have been
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OPEN-CTO study. Each participating site ob-
tained institutional research board approval,
and all patients provided written
informed consent.
Among the 1,000 patients enrolled in the
OPEN-CTO registry, we examined all patients
who had angiographic perforation assessed
by the core lab (Figure 1). Incidence of major adverse
events (MAEs) and each individual component of
MAE among patients with perforation were assessed.
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FIGURE 2 7 Categories of Perforation Shapes
(A) Round, (B) oval, (C) spotty, (D) cloud-like, (E) floating, (F) mushroom-like, (G) around the vessel. The yellow arrows indicate the site of perforation.
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1904core lab. Clinical perforation was defined as any
perforation requiring treatment (6). MAE was defined
as in-hospital death, pericardial effusion, and peri-
cardial tamponade. Technical success of the proced-
ure was defined as <50% residual stenosis and TIMI
flow grade 2 or 3 at the conclusion of the procedure,
as well as no side branch occlusion (6).
All procedural angiograms were reviewed by an
angiographic core laboratory (Saint Luke’s Mid
America Heart Institute, Kansas City, Missouri) using
QAngio XA 7.3 (Medis Medical Imaging Systems, Lei-
den, the Netherlands) software (7). Each perforation
was evaluated for maximal area, length, location,
shape, presence of staining, speed of filling, speed of
drainage, and strategy that caused the perforation.
Area and length were measured at the first fluoros-
copy or cine run after the perforation occurred when
the perforation was maximal size. The shape was
categorized into 7 patterns (oval, round, spotty,
cloud-like, floating, mushroom-like, and around the
vessel) (Figure 2). The presence of staining was
defined as any contrast remnant at the perforation
site during subsequent imaging. The filling speed was
evaluated by assessing the number of heartbeats ittook until the density of the perforation was at
maximum after the contrast injection. Similarly, the
drainage speed was defined as number of heartbeats
it took before the density of the perforation started to
decrease. Septal perforations were defined as identi-
fication of any contrast extending outside of the
borders of the septal artery during angiography
and/or persistence of contrast near or around a septal
artery after all contrast had left the coronary artery
tree. When there was any question regarding the
assessment, the angiogram was over-read by the se-
nior author (J.A.G.), and consensus was achieved.
The strategy that caused the perforation was
defined as the last strategy used before the fluoros-
copy or cine run documented the perforation. Perfo-
rations that occurred with the antegrade preparation
during a retrograde approach or any proximal vessel
ballooning during reverse controlled antegrade and
retrograde tracking technique were categorized as
perforations during the retrograde approach.
STATISTICAL ANALYSES. The demographics, clinical
characteristics, lesion characteristics, MAE, and
strategy that caused perforation were assessed in all







Age, yrs 72.2  7.9 68.4  8.2 0.03
Male 36 (83.7) 40 (87.0) 0.67
Hypertension 39 (90.7) 43 (93.5) 0.71
Diabetes 16 (37.2) 23 (50.0) 0.22
Prior myocardial infarction 21 (48.8) 28 (60.9) 0.25
Prior CABG 24 (55.8) 28 (60.9) 0.63
Prior coronary stenting 33 (76.7) 33 (71.7) 0.59
Peripheral arterial disease 8 (18.6) 10 (21.7) 0.71
History of stroke/TIA 4 (9.3) 0 (0.0) 0.05
Chronic kidney disease 8 (18.6) 9 (19.6) 0.90
LV systolic function 0.66
Normal 22 (55.0) 18 (45.0)
Mildly reduced 9 (22.5) 8 (20.0)
Moderately reduced 4 (10.0) 7 (17.5)
Severely reduced 5 (12.5) 7 (17.5)
LVEF 46.5  14.8 44.1  14.8 0.15
Values are mean  SD or n (%).
CABG ¼ coronary artery bypass grafting; LV ¼ left ventricular; LVEF ¼ left ventricular ejection
fraction; TIA ¼ transient ischemic attack.
TABLE 2 Procedural Characteristics and Approach Used During







CTO target vessel 0.39
RCA 27 (62.8) 35 (76.1)
LAD 7 (16.3) 5 (10.9)
LCx 9 (20.6) 6 (13.0)
Left main 0 (0) 0 (0)
Mean J-CTO score 2.9  1.1 3.0  1.3 0.66
Calcification 23 (53.5) 19 (41.3) 0.25
Severe tortuosity 30 (69.8) 33 (71.7) 0.84
Approach
Antegrade only 7 (16.3) 11 (23.9) 0.60
Retrograde only 11 (25.6) 9 (19.6)
Both approaches 25 (58.1) 26 (56.5)
Values are n (%) or mean  SD.
CTO ¼ chronic total occlusion; J-CTO ¼ Japanese Multicenter CTO Registry;
LAD ¼ left anterior descending coronary artery; LCx ¼ left circumflex coronary
artery; PCI ¼ percutaneous coronary intervention; RCA ¼ right coronary artery.
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1905participants. The characteristics of perforation be-
tween clinical and nonclinical perforations were
compared using Student’s t-test for continuous vari-
ables and chi-square tests for categorical variables.
Similarly, characteristics of perforations between
those with and without MAE were compared. All
statistical analyses were performed with SAS version
9.4 (SAS Institute, Cary, North Carolina).
RESULTS
The baseline characteristics of patients with angio-
graphic perforation are summarized in Table 1. Over-
all, the mean age was 70.2  8.2 years, and 50% of
patients had reduced ejection fraction. There was no
difference in the frequency of prior history of coro-
nary artery bypass grafting (CABG) between patients
with clinical and nonclinical perforations (55.8% vs.
60.9%; p ¼ 0.63). The procedural and lesion charac-
teristics, and approach used during CTO PCI are
summarized in Table 2. An antegrade-only approach
was used in 20.2% of the patients, a retrograde-only
approach in 22.5%, and both approaches were used
in 57.3%.
Among the 89 patients with angiographic perfora-
tion, 43 (48.3%) had clinical perforation requiring
treatment. The combined MAE rate was 28.0% and
included 9 in-hospital deaths (10.1%), 21 pericardial
effusions (23.5%), and 10 cases of cardiac tamponade
(11.2%) (Table 3). Most MAE occurred in patients with
clinical perforation, except for 3 patients with
nonclinical perforation who developed pericardial
effusion (Table 3). Five of 9 patients with fatal
perforation died during the procedure. Four of the
fatal perforations occurred among subjects with a
history of CABG, and 5 fatal perforations occurred
among non-CABG patients. Two of 9 patients also had
procedure-related myocardial infarction. There were
no additional deaths at 1 year. The treatment per-
formed for clinical perforation is summarized in
Table 4. Prolonged balloon inflation was performed in
10 patients (23.3%), covered stent in 12 patients
(27.9%), aspiration in 4 patients (9.3%), and emboli-
zation in 17 patients (39.5%). All 10 patients with
cardiac tamponade underwent either pericardiocent-
esis (n ¼ 6 [6.7%]) or surgical creation of a pericardial
window (n ¼ 4 [4.1%]). Among the 4 patients that
required pericardial window, 2 had a prior history of
CABG, and 2 had no prior history of CABG. Among the
6 patients that required pericardiocentesis, 1 had a
prior history of CABG, and 5 had no history of CABG.
There were no patients treated with ultrasound or
computed tomography-guided posterior drainage, or
intentional septal rupture for decompression.The angiographic characteristics comparing clinical
and nonclinical perforation are summarized in
Table 5. Compared with nonclinical perforations,
clinical perforations were larger in size (152.2 
199.5 mm2 vs. 66.4  47.9 mm2; p < 0.01), and more
frequently occurred within a septal perforator or
epicardial collateral vessel (23.3% vs. 4.3%; p ¼ 0.03),
had a high-risk shape (defined as cloud-like or
floating [34.9% vs. 4.4%; p < 0.01]), and less likely to










Combined adverse events 22 (51.2) 3 (6.5) 25 (28.0) <0.01
In-hospital death 9 (20.9) 0 (0.0) 9 (10.1) <0.01
Pericardial effusion 18 (41.9) 3 (6.5) 21 (23.5) <0.01
Cardiac tamponade 10 (23.3) 0 (0.0) 10 (11.2) <0.01
Pericardiocentesis 6 (14.0) 0 (0.0) 6 (6.7) 0.01
Pericardial window 4 (9.3) 0 (0.0) 4 (4.1) 0.05
Values are n (%).
MAE ¼ major adverse events.








Size area, mm2 152.2  199.5 66.4  47.9 <0.01
Location 0.03
Proximal 9 (20.9) 9 (19.6)
Nonproximal 24 (55.8) 35 (76.1)
Collateral* 10 (23.3) 2 (4.3)
High-risk shape† 15 (34.9) 2 (4.4) <0.01
Staining 29 (67.4) 40 (87.0) 0.03
Epicardial 8 (18.6) 0 (0.0) <0.01
Fast filling 32 (84.2) 22 (62.9) 0.04
Fast drainage 10 (23.3) 4 (8.7) 0.06
Values are mean  SD or n (%). *Collateral was defined as epicardial vessel or
septal perforator. †High-risk shape included cloud-like and floating.





Event (n ¼ 64)
p
Value
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1906have staining (67.4% vs. 87.0%; p < 0.03). In addition,
all 8 perforations that occurred in epicardial collateral
vessels were clinical perforations. Compared with
nonclinical perforations, clinical perforations were
more likely to be fast filling (84.2% vs. 62.9%;
p < 0.04) and had a higher frequency of being fast
draining (23.3% vs. 8.7%; p ¼ 0.06).
The angiographic characteristics comparing perfo-
rations with MAE and without MAE are summarized
in Table 6. Compared with perforations with no MAE,
perforations with MAE were larger in size (173.2 
155.2 mm2 vs. 83.2  139.9 mm2; p ¼ 0.01), more
proximal or at a collateral location (p < 0.01) and had
a high-risk shape (p < 0.01). The frequency of
epicardial location was numerically higher. Compared
with perforations without a MAE, the frequency of
staining, being fast filling, and having faster drainage
were similar in perforations with MAE.
When the mechanism of perforations was assessed
by the core lab, among the 51 patients who had both
antegrade and retrograde approaches during the CTO
PCI, perforation occurred during the antegrade
attempt in 31 patients (60.1%) (Figure 3). Overall, 49
of the perforations (55.1%) occurred during the ante-
grade strategy, and 40 (44.9%) occurred during the
retrograde strategy. Among the 49 antegradeTABLE 4 Treatment Performed for Clinical Perforation (N ¼ 43)
Prolonged balloon inflation 10 (23.3)




Pericardial window 4 (9.3)
Values are n (%).perforations, 18 (20.2%) occurred during an antegrade
wire escalation (AWE) attempt, and 31 (34.8%)
occurred during an antegrade dissection re-entry
(ADR) attempt. Among the 40 retrograde perfora-
tions, 19 (21.3%) occurred during a retrograde wire
escalation attempt, and 21 (23.6%) occurred during a
retrograde dissection re-entry attempt (Figure 4). The
perforation rate among each strategy applied was as
follows: AWE 2.8% (18 of 639), ADR 7.8% (31 of 400),
retrograde wire escalation 7.2% (19 of 263), and
retrograde dissection re-entry 5.9% (21 of 353);
p ¼ 0.002.
Figure 5 summarizes all 49 of the antegrade per-
forations. The location of the triangle marks the
anatomic location of perforation. The size of the tri-
angle represents the measured size of the perforation.
Clinical perforations are colored in red, andSize area, mm2 173.2  155.2 83.2  139.9 0.01
Location <0.01
Proximal 7 (28.0) 11 (17.2)
Nonproximal 10 (40.0) 51 (79.7)
Collateral* 8 (32.0) 2 (3.1)
High-risk shape† 13 (52.0) 9 (14.3) <0.01
Staining 19 (76.0) 50 (78.1) 0.83
Epicardial 6 (24.0) 2 (3.1) 0.11
Fast filling 18 (85.7) 36 (69.2) 0.15
Fast drainage 4 (16.0) 10 (15.6) 1.00
Values are mean  SD or n (%). *Collateral was defined as epicardial vessel or
septal perforator. †High-risk shape included cloud-like and floating.
MAE ¼ major adverse events.
FIGURE 3 Operator-Reported Approach Used and the Actual Antegrade/Retrograde Strategy That Caused Perforation
FIGURE 4 Strategy That Caused Perforation
ADR ¼ antegrade dissection re-entry; AWE ¼ antegrade
wire escalation; RDR ¼ retrograde dissection re-entry;
RWE ¼ retrograde wire escalation.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 1 2 , N O . 1 9 , 2 0 1 9 Hirai et al.
O C T O B E R 1 4 , 2 0 1 9 : 1 9 0 2 – 1 2 Perforation and CTO PCI
1907nonclinical perforations are colored in green. The 2
perforations that were associated with in-hospital
death are marked with a lightning mark. In this
figure, major complications appear to occur more
often in more proximal perforations, especially in the
right coronary artery. The frequency of clinical
perforation is lower with distal perforations.
Similarly, Figure 6 summarizes all 40 perforations
that occurred during the retrograde attempt. The
location and size of the circle represents the location
and measured size of the perforation; clinical perfo-
rations are colored in red, and nonclinical perfora-
tions are colored in green. Notably, all 8 perforations
that occurred in the epicardial vessels were clinical
perforations, and among the 8 patients, 4 had an in-
hospital death, which represents the most fatal
perforation type. A summary of all 89 perforations are
presented in the Central Illustration.
DISCUSSION
Perforation is the most frequent and important
complication in CTO PCI, because it can lead to sig-
nificant adverse outcomes including in-hospital
death. In the OPEN-CTO registry, all 9 in-hospital
deaths occurred in patients with a clinical perfora-
tion. Accordingly, it is critical to understand the
mechanism and high-risk features of perforations in
the setting of CTO PCI. In the first study to describe
the detailed angiographic characteristics experienced
by patients undergoing CTO PCI, we found that larger
size, collateral location, a high-risk shape, lessstaining, fast filling, and fast drainage were associ-
ated with clinically important perforations requiring
treatment. High-risk perforations included “cloud-
like” and “floating” among the 7 shapes evaluated.
Most of the major adverse outcomes occurred in
clinical (treated) perforations except for 3 pericardial
effusions not leading to tamponade, which suggests
that experienced operators are appropriately select-
ing the perforations that require treatment.
FIGURE 5 Summary of All Perforations Caused by Antegrade Strategy
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1908On the other hand, factors associated with adverse
outcomes, defined as in-hospital death, pericardial
effusion, and cardiac tamponade, were larger size,
collateral or proximal location, and high-risk shape. In
contrast to perforations requiring treatment, staining,
fast filling, and fast drainage were not significantly
associated with adverse outcome. Most of our findings
are expected because the larger size perforation likely
represents a larger hole or rapid bleeding. Moreover,
proximal portions of coronary vessels have faster
blood flow and higher coronary pressure, andFIGURE 6 Summary of All Perforations Caused by Retrograde Stratcollateral perforations are more difficult to detect and
control. Interestingly, staining, fast filling, and fast
drainage were predictors for treatment (clinical
perforation), but not adverse outcome. Our findings
suggest that CTO operators should not be reassured on
the basis of the presence of staining and slow speed of
filling and drainage alone when encountering coro-
nary perforation and should give more consideration
to location, shape, and size.
In our study, we found that 55.8% of patients with
clinical perforations occurred in patients with a prioregy
CENTRAL ILLUSTRATION Summary of Size and Location of Clinical and Nonclinical Perforations
From the OPEN-CTO Registry
Hirai, T. et al. J Am Coll Cardiol Intv. 2019;12(19):1902–12.
OPEN-CTO ¼ Outcomes, Patient health status, and Efficiency iN Chronic Total Occlusion hybrid procedures registry.
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TABLE 7 Summary of Previous Studies Comparing Antegrade and Retrograde Approaches













Attempt was made to
cross the collateral
channel supplying the
distal vessel to the
target CTO lesion.
PRA: Procedures initially
planned to cross the
CTO lesion with
retrograde approach.
87.3% N/A 0.9% (perforation
with tamponade)
Overall technical success
rate was high, and the
complication rate was
low.















target vessel distal to
the lesion.














as “retrograde” if the
retrograde approach
was used at any point
during the procedure.
85.5% 4.5% 2.9% Compared with AWE, use




may carry higher risk
but is used in more
complex lesions.
A>R Single center, VA
population.
A ¼ antegrade; ADR ¼ antegrade dissection re-entry; AWE ¼ antegrade wire escalation; CTO ¼ chronic total occlusion; MACCE ¼ major adverse cardiovascular and cerebrovascular events; MI ¼ myocardial
infarction; N/A ¼ not applicable; PRA ¼ primary retrograde approach; R ¼ retrograde.
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1910history of CABG. Among the 25 patients with MAE, 13
patients (52%) had a history of CABG. This finding
underscores that post-CABG patients are at equal risk
for adverse events compared with non-CABG pa-
tients. We highlight this finding because there seems
to be a common misconception that “post-CABG pa-
tients are safer, and perforation does not lead to
tamponade due to previous pericardiotomy.”
Our study is the first study, to the best of our
knowledge, to determine the strategy that caused
perforation on the basis of core lab review. We found
that among 51 patients who had both antegrade and
retrograde approaches, 31 patients (60.8%) had
perforation during an antegrade approach. This is an
important finding because, except for 1 study that
compared antegrade and retrograde on the basis of
the primary strategy (8), previous studies that have
reported an increased risk with retrograde procedures
have classified retrograde as any retrograde attempt
(9,10) (Table 7). Both of these studies have concluded
that the retrograde strategy was higher risk compared
with the antegrade strategy. If we had compared our
data in a similar fashion, only 18 of the perforations
(20.2%) would have been classified as antegrade.
However, with the core lab analysis, a total of 49 of
the perforations (55.1%) were caused during the
antegrade attempt, including the 31 patients who had
both antegrade and retrograde attempts but had the
perforation during the antegrade strategy. Thisfinding suggests that the reported complication rates
from previous studies cannot be attributed solely to
the retrograde strategy itself and may be related to the
complex anatomy in patients undergoing a retrograde
or combined strategy compared with an antegrade-
only strategy. Future studies need to take the strat-
egy that caused perforation into account when
comparing antegrade and retrograde approaches.
Among each strategy applied, AWE had the lower
perforation rate. Dedicated hybrid operators in the
OPEN-CTO registry did not perform AWE for long le-
sions (>20 mm). In addition, if AWE was selected as
the initial strategy for short lesions (<20 mm) they
switched to ADR once the guidewire entered the
subintimal space (according to the hybrid algorithm).
Therefore, the lower perforation rate of AWE is likely
confounded by selection bias, and we cannot draw
any definitive conclusion regarding the safety of each
approach. ADR has been proven safe and effective in
the FAST-CTOs (Facilitated Antegrade Steering
Technique in Chronic Total Occlusions) (11) and
CrossBoss First (12) trials.
In the present study, we found higher than ex-
pected risk of MAE when perforations occur at the
epicardial collateral vessels. This is in line with the
previous study that reported higher complication rate
when an ipsilateral collateral channel was used (13)
and is most likely related to the increased risk of
pericardial effusion/cardiac tamponade, given the
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1911anatomy and the difficulty controlling the bleeding
due to dual blood supply from both antegrade and
retrograde arteries. This finding suggests that
epicardial collateral vessels should be reserved as a
last resort when planning CTO PCI. In particular, less
experienced operators may need to compare the risk
of epicardial collateral vessels when perforations
occur with safer antegrade bailout options such as
subintimal tracking and re-entry technique (14) or
subintimal plaque modification technique (15) when
no other options are available.
Kinnaird et al. (4) have recently reported the
“legacy effect” of perforations by demonstrating
increased mortality at follow-up after perforation.
Contrary to their findings, we did not find any addi-
tional mortality after hospital discharge among pa-
tients with a perforation. The reason for this is
unclear, but possible explanations include difference
in study size, population, and management tech-
niques. Because their study included perforations
reported by the operator, and our study was core lab
adjudicated, it is possible that severe perforations
were selectively reported in their study as evidenced
by the lower clinical perforation rate 1.4% compared
with our study (4.3% clinical perforation rate).
Because our study included only experienced opera-
tors in high-volume centers, it is possible that the
speed of recognition and management after perfora-
tion may have played a role as evidenced by prompt
treatment in patients with perforation in our study.
STUDY LIMITATIONS. These results should be
considered in the context of the following potential
limitations. First, this study examined a population of
patients referred for CTO PCI at experienced CTO PCI
centers. Accordingly, the prevalence of perforation
among patients with CTOs in the broader population
cannot be determined from this study, and these data
may not be generalizable to all care settings. Second,
the time from perforation to response, time to initi-
ation of treatment, or activated clotting time at the
time of perforation was not systematically collected.
Third, the strength of contrast injection by the oper-
ator and the length of cine run could have affected
the perforation size and filling speed. In some
obvious cases of perforation, the perforation could
have been underestimated by the treatment initiated
by the operator after very gentle injection. However,
in the majority of perforation cases, the cine/fluo-
roscopy run was obtained until maximal filling of
contrast. Fourth, the effect of different types of
treatment strategies was not taken into account when
comparing patients with adverse outcomes and pa-
tients without adverse outcomes. Fifth, althoughperforation of epicardial collateral vessels appears to
be high risk, whether the epicardial collateral vessels
were used was not systemically collected in the total
population. Therefore, the frequency of epicardial
perforation among all patients who had an epicardial
attempt could not be determined. Sixth, the strategy
of perforation was defined as the strategy that was
used right before the perforation was noticed by
angiogram, and it is possible in some cases that the
perforation had occurred with a previous strategy
(i.e., wire escalation) and became evident during the
following strategy (i.e., dissection re-entry). Seventh,
the relationship of size, locations, and other factors,
and the risk of clinical deterioration might vary be-
tween main, septal, and epicardial collateral vessels.
Given the relatively small number of clinical perfo-
rations, we are unable to account for potential con-
founding by multivariate analysis. Larger future
studies will need to be conducted to identify the in-
dependent associations with outcomes Eighth, this
study described the perforation pattern among
experienced hybrid operators. With the lower use of
subintimal space in non-hybrid operators, especially
among experienced Japanese operators (16), it is
possible that perforation patterns are also different,
and this requires further study. Ninth, because the
perforations were identified by the core lab using
angiograms without time stamping, the exact time of
the perforation during the case could not
be ascertained.
CONCLUSIONS
We found that experienced operators from the OPEN-
CTO registry appropriately selected perforations that
required treatment. Larger size, proximal or collateral
location, and high-risk shape were associated with
adverse outcomes. In patients undergoing CTO PCI
using both antegrade and retrograde approaches, 6 of
10 perforations occurred during an antegrade
attempt. Therefore, when performing antegrade and
retrograde comparison, the strategy that caused the
perforation should be taken into account. These
findings should help both current and emerging CTO
operators avoid perforations, understand high-risk
features, and better triage perforation treatment
during CTO PCI.
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PERSPECTIVES
WHAT IS KNOWN? Perforation is the most frequent
and important complication in CTO PCI because it can lead
to significant adverse outcomes, including in-hospital
death.
WHAT IS NEW? Perforations that lead to adverse
outcomes during the CTO PCI were larger in size, had a
proximal or collateral location, and had a high-risk shape.
In patients undergoing CTO PCI using both antegrade and
retrograde approaches, 6 of 10 perforations occurred
during an antegrade attempt. Therefore, when
performing antegrade and retrograde comparison, the
strategy that caused the perforation must be taken into
account.
WHAT IS NEXT? Further studies are needed to
determine the individual risk estimation for perforation
and strategies to reduce perforation rates and adverse
outcomes related to perforations during CTO PCI.
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